- Home
- ORGN vs SKYE Comparison
ORGN vs SKYE Comparison
Compare ORGN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- SKYE
- Stock Information
- Founded
- ORGN 2008
- SKYE 2012
- Country
- ORGN United States
- SKYE United States
- Employees
- ORGN N/A
- SKYE N/A
- Industry
- ORGN Major Chemicals
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ORGN Industrials
- SKYE Health Care
- Exchange
- ORGN Nasdaq
- SKYE Nasdaq
- Market Cap
- ORGN 96.4M
- SKYE 80.7M
- IPO Year
- ORGN N/A
- SKYE N/A
- Fundamental
- Price
- ORGN $0.67
- SKYE $1.81
- Analyst Decision
- ORGN Strong Buy
- SKYE Buy
- Analyst Count
- ORGN 1
- SKYE 6
- Target Price
- ORGN $3.00
- SKYE $16.60
- AVG Volume (30 Days)
- ORGN 720.1K
- SKYE 1.7M
- Earning Date
- ORGN 05-15-2025
- SKYE 05-08-2025
- Dividend Yield
- ORGN N/A
- SKYE N/A
- EPS Growth
- ORGN N/A
- SKYE N/A
- EPS
- ORGN N/A
- SKYE N/A
- Revenue
- ORGN $31,282,000.00
- SKYE N/A
- Revenue This Year
- ORGN $49.18
- SKYE N/A
- Revenue Next Year
- ORGN $144.81
- SKYE N/A
- P/E Ratio
- ORGN N/A
- SKYE N/A
- Revenue Growth
- ORGN 8.60
- SKYE N/A
- 52 Week Low
- ORGN $0.42
- SKYE $1.14
- 52 Week High
- ORGN $1.90
- SKYE $13.49
- Technical
- Relative Strength Index (RSI)
- ORGN 47.17
- SKYE 48.48
- Support Level
- ORGN $0.64
- SKYE $1.36
- Resistance Level
- ORGN $0.71
- SKYE $2.30
- Average True Range (ATR)
- ORGN 0.06
- SKYE 0.21
- MACD
- ORGN 0.00
- SKYE 0.02
- Stochastic Oscillator
- ORGN 16.65
- SKYE 42.35
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.